Se‐Hoon Lee

机构：Yong In University, Samsung (South Korea), Samsung Medical Center, Seoul Medical Center, Bristol-Myers Squibb (South Korea), Sungkyunkwan University · ORCID：0000-0002-9219-3350

发表论文 1143 篇 · 总被引 33757 次 · h-index 87

代表论文

• Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer (2026 · European Journal of Cancer)
• Feasibility of mobile device-based patient-reported outcomes in real-world clinical settings for non-small cell lung cancer (2026 · Precision and Future Medicine)
• Supplementary Figure S1 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression (2026)
• Supplementary Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer (2026)
• Supplementary Figure S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression (2026)
• Supplementary Figure S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression (2026)